IRIS
DUMINUCO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.124
AS - Asia 893
EU - Europa 666
AF - Africa 181
SA - Sud America 107
OC - Oceania 4
Totale 2.975
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.101
IT - Italia 498
CN - Cina 375
SG - Singapore 343
CI - Costa d'Avorio 146
KR - Corea 116
BR - Brasile 93
IE - Irlanda 51
FI - Finlandia 28
SN - Senegal 20
IN - India 18
DE - Germania 14
MX - Messico 11
HK - Hong Kong 10
GB - Regno Unito 9
UA - Ucraina 9
BE - Belgio 8
CA - Canada 8
VN - Vietnam 8
BD - Bangladesh 7
CZ - Repubblica Ceca 7
FR - Francia 7
NL - Olanda 7
PL - Polonia 6
RU - Federazione Russa 6
SE - Svezia 6
ZA - Sudafrica 6
IQ - Iraq 5
VE - Venezuela 5
AR - Argentina 4
AU - Australia 4
NG - Nigeria 4
ES - Italia 3
TR - Turchia 3
AL - Albania 2
BO - Bolivia 2
JP - Giappone 2
KE - Kenya 2
PK - Pakistan 2
BF - Burkina Faso 1
BH - Bahrain 1
CH - Svizzera 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
LB - Libano 1
OM - Oman 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SC - Seychelles 1
SI - Slovenia 1
SO - Somalia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 2.975
Salva come PNG Salva come JPEG
Città #
Dallas 343
Singapore 243
Santa Clara 233
Hefei 225
Abidjan 146
Seoul 116
Chicago 114
Catania 81
Ashburn 64
Dublin 49
Civitanova Marche 48
Chandler 43
Los Angeles 42
Boardman 38
Rome 37
Beijing 36
Milan 33
Palermo 31
Dakar 20
Lappeenranta 14
Florence 12
Bari 11
Hong Kong 10
Helsinki 9
Misterbianco 9
Bronte 8
Brussels 8
Messina 8
Munich 8
Turin 8
Naples 7
Cambridge 6
Chennai 6
Lawrence 6
New York 6
Rio de Janeiro 6
Warsaw 6
Washington 6
Boston 5
Cassano delle Murge 5
Johannesburg 5
Piazzola Sul Brenta 5
San Francisco 5
San Giovanni la Punta 5
Seattle 5
São Paulo 5
Turku 5
Abuja 4
Amsterdam 4
Belo Horizonte 4
Brno 4
Frankfurt am Main 4
Genoa 4
Mexico City 4
Paris 4
Aci Sant'Antonio 3
Atlanta 3
Lamezia Terme 3
Melbourne 3
Olomouc 3
Piacenza 3
Pozzallo 3
Santa Venerina 3
Stockholm 3
Örebro 3
Acireale 2
Ancona 2
Andover 2
Annapolis 2
Bologna 2
Campinas 2
Can Tho 2
Caselle Torinese 2
Cernusco sul Naviglio 2
Cornaredo 2
Council Bluffs 2
Curitiba 2
Denver 2
Galloway 2
Ho Chi Minh City 2
Hải Dương 2
Kochi 2
London 2
Lonigo 2
Manassas 2
Mascalucia 2
Melilli 2
Montreal 2
Nairobi 2
Orvieto 2
Paternò 2
Pedara 2
Phoenix 2
Pirenópolis 2
Porto Alegre 2
Praia Grande 2
Pune 2
Ribeirão Preto 2
Santa Maria 2
Santos 2
Totale 2.273
Salva come PNG Salva come JPEG
Nome #
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 123
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 112
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 107
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 104
A case of high-risk AML in a patient with advanced systemic mastocytosis 98
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 97
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 92
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 85
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 83
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 83
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 81
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 80
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 79
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 76
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study 75
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 75
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 73
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 72
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 71
Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report 70
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 69
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 69
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 68
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 67
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study 67
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 65
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes 64
Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature's review 62
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 62
VEXAS-like syndrome: a potential new entity? 62
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases 57
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association 55
Emergencies in Hematology: Why, When and How I Treat? 54
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 54
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors 51
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease 50
Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma 46
Emerging Therapeutic Approaches for Anemia in Myelofibrosis 45
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey 40
Myelofibrosis: In Search for BETter Targeted Therapies 39
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms 34
Chemotherapy extravasation: diagnosis, prevention and management 34
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? 29
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study 25
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib 20
Totale 3.024
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.588
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.588
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202252 0 0 0 0 6 4 3 1 6 14 5 13
2022/2023230 7 15 5 12 12 20 7 43 51 14 34 10
2023/2024474 26 60 22 55 13 88 33 36 6 17 80 38
2024/20251.189 16 174 41 114 190 121 60 45 71 85 123 149
2025/20261.079 226 425 411 17 0 0 0 0 0 0 0 0
Totale 3.024